Floatz logo

CIS-DIAMMINEDICHLOROPLATINUM II

Atypical Chronic Myeloid Leukemia

National Cancer Institute (NCI)Small moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the Atypical Chronic Myeloid Leukemia cohort.

Asset / SponsorPhaseRating
TACROLIMUS
Fred Hutchinson Cancer Center
Phase 2B
Vinorelbine
OHSU Knight Cancer Institute
Phase 2B
Carboplatin
OHSU Knight Cancer Institute
Phase 2B
Ruxolitinib
St. Petersburg State Pavlov Medical University
Phase 2B
METHOTREXATE
Fred Hutchinson Cancer Center
Phase 2B

View all 10 →

Same molecule, other indications

CIS-DIAMMINEDICHLOROPLATINUM II is also rated in:

squamous cell lung carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
primary peritoneal carcinomaDormant
BBB
Indicative ·
77 / 100
View asset →
adenocarcinomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →